Pharma firm Gilead to raise Galapagos stake in $5.1 billion deal - report

(Reuters) - Gilead Sciences Inc will increase its stake in Galapagos NV and gain rights outside Europe to the Belgian-Dutch biotech firm's treatments in development in a $5.1 billion deal, the Wall Street Journal reported on Sunday.U.S. drugmaker Gilead will invest $1.1 billion, or 140.59 euros (126.01 pounds) per share to increase its stake in Galapagos to 22% from 12.3%, and make a separate $3.95 billion payment to Galapagos, WSJ said.The terms of the deal, including the research..